ATE304371T1 - Verwendung von staphylococcus enterotoxin homologe für krebs-therapie - Google Patents

Verwendung von staphylococcus enterotoxin homologe für krebs-therapie

Info

Publication number
ATE304371T1
ATE304371T1 AT01104586T AT01104586T ATE304371T1 AT E304371 T1 ATE304371 T1 AT E304371T1 AT 01104586 T AT01104586 T AT 01104586T AT 01104586 T AT01104586 T AT 01104586T AT E304371 T1 ATE304371 T1 AT E304371T1
Authority
AT
Austria
Prior art keywords
homologue
cancer therapy
staphylococcus enterotoxin
enterotoxin
staphylococcus
Prior art date
Application number
AT01104586T
Other languages
English (en)
Inventor
David S Terman
Jay L Stone
Original Assignee
David S Terman
Jay L Stone
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23852299&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE304371(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by David S Terman, Jay L Stone filed Critical David S Terman
Application granted granted Critical
Publication of ATE304371T1 publication Critical patent/ATE304371T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/45—Bacterial antigens
    • A61K40/4532—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/45—Bacterial antigens
    • A61K40/4534—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT01104586T 1990-01-17 1991-01-17 Verwendung von staphylococcus enterotoxin homologe für krebs-therapie ATE304371T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US46657790A 1990-01-17 1990-01-17

Publications (1)

Publication Number Publication Date
ATE304371T1 true ATE304371T1 (de) 2005-09-15

Family

ID=23852299

Family Applications (3)

Application Number Title Priority Date Filing Date
AT91903963T ATE220688T1 (de) 1990-01-17 1991-01-17 Tumor-zerstörende effekte von enterotoxinen und verwandten verbindungen
AT01102715T ATE303157T1 (de) 1990-01-17 1991-01-17 Verwendung von staphylococcus-enterotoxinen oder verwandte verbindungen für krebs-therapie
AT01104586T ATE304371T1 (de) 1990-01-17 1991-01-17 Verwendung von staphylococcus enterotoxin homologe für krebs-therapie

Family Applications Before (2)

Application Number Title Priority Date Filing Date
AT91903963T ATE220688T1 (de) 1990-01-17 1991-01-17 Tumor-zerstörende effekte von enterotoxinen und verwandten verbindungen
AT01102715T ATE303157T1 (de) 1990-01-17 1991-01-17 Verwendung von staphylococcus-enterotoxinen oder verwandte verbindungen für krebs-therapie

Country Status (5)

Country Link
EP (3) EP1129717B2 (de)
AT (3) ATE220688T1 (de)
CA (1) CA2078003C (de)
DE (3) DE69133485T2 (de)
WO (1) WO1991010680A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6042837A (en) * 1989-09-20 2000-03-28 Kalland; Terje Methods of staphylococcal enterotoxin directed cell-mediated cytotoxicity (SDCC)
SE8903100D0 (sv) † 1989-09-20 1989-09-20 Pharmacia Ab New pharmaceutical agent
US5728388A (en) 1989-10-03 1998-03-17 Terman; David S. Method of cancer treatment
US6126945A (en) * 1989-10-03 2000-10-03 Pharmacia Ab Tumor killing effects of enterotoxins, superantigens, and related compounds
WO1993024136A1 (en) * 1991-01-17 1993-12-09 Terman David S Tumor killing effects of enterotoxins, superantigens, and related compounds
US5529934A (en) * 1991-07-29 1996-06-25 Biomide Investment Limited Partnership Method for measuring blood procoagulant activity of human leukocyte antigens
JPH08500328A (ja) * 1992-01-28 1996-01-16 ナショナル ジューイッシュ センター フォア イミュノロジィ アンド レスパラトリィ メディスン 突然変異したスーパー抗原の保護作用
EP0705104A4 (de) * 1993-03-02 1997-06-18 David S Terman Methode zur krebsbehandlung
US5585465A (en) * 1993-04-05 1996-12-17 National Jewish Center For Immunology And Respiratory Medicine Isolated toxin associated with Kawasaki syndrome
SE9402430L (sv) 1994-07-11 1996-01-12 Pharmacia Ab Konjugat mellan modifierat superantigen och en målsökande förening samt användning av konjugaten
US5626838A (en) * 1995-03-13 1997-05-06 The Procter & Gamble Company Use of ketorolac for treatment of squamous cell carcinomas of the oral cavity or oropharynx
US5935568A (en) * 1995-05-18 1999-08-10 National Jewish Medical & Research Center Gene therapy for effector cell regulation
SE9601245D0 (sv) 1996-03-29 1996-03-29 Pharmacia Ab Chimeric superantigens and their use
TW517061B (en) 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
IL119938A (en) 1996-12-30 2005-08-31 Yissum Res Dev Co Peptides capable of eliciting protective immunity against toxic shock induced by pyrogenic exotoxins or of antagonizing toxin-mediated activation of t cells
US6075119A (en) * 1997-04-07 2000-06-13 The Rockefeller University Peptides useful for reducing symptoms of toxic shock syndrome
US6872394B1 (en) 1997-12-02 2005-03-29 Idaho Research Foundation, Inc. Non-toxic immune stimulating enterotoxin compositions
AU6059799A (en) * 1998-10-07 2000-04-26 Rockefeller University, The Peptides useful for reducing symptoms of toxic shock syndrome and septic shock
SE0102327D0 (sv) 2001-06-28 2001-06-28 Active Biotech Ab A novel engineered superantigen for human therapy
WO2018225063A1 (en) * 2017-06-04 2018-12-13 Rappaport Family Institute For Research In The Medical Sciences Method of predicting personalized response to cancer treatment with immune checkpoint inhibitors and kits therefor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE91237T1 (de) * 1986-10-16 1993-07-15 Harvard College Kombinationen von nekrose-tumor-faktoren und entzuendungshemmenden mitteln fuer die behandlung von boesartigen und nicht boesartigen erkrankungen.
SE8801426D0 (sv) * 1988-04-15 1988-04-15 Ulf Rothman Forfarande och medel for blodbehandling
SE8903100D0 (sv) * 1989-09-20 1989-09-20 Pharmacia Ab New pharmaceutical agent

Also Published As

Publication number Publication date
EP1129717B1 (de) 2005-09-14
DE69133484D1 (de) 2005-10-06
EP1103268A1 (de) 2001-05-30
DE69133485D1 (de) 2005-10-20
DE69133484T2 (de) 2006-05-18
EP1129717A1 (de) 2001-09-05
DE69133068T2 (de) 2003-03-13
ATE220688T1 (de) 2002-08-15
EP0511306A1 (de) 1992-11-04
EP0511306A4 (en) 1993-04-28
DE69133485T2 (de) 2006-06-22
ATE303157T1 (de) 2005-09-15
EP0511306B1 (de) 2002-07-17
CA2078003A1 (en) 1991-07-18
EP1103268B1 (de) 2005-08-31
WO1991010680A1 (en) 1991-07-25
DE69133068D1 (de) 2002-08-22
CA2078003C (en) 2006-11-21
EP1129717B2 (de) 2013-03-06

Similar Documents

Publication Publication Date Title
ATE304371T1 (de) Verwendung von staphylococcus enterotoxin homologe für krebs-therapie
HUP9802212A2 (hu) Humán terápiában alkalmazható rekombináns anti-CD4-ellenanyagok
DK0690720T3 (da) Terapeutiske anvendelser af baktericide/permeabilitetsforøgende proteinprodukter
DE69112435D1 (de) Verdampfer für anästhetische Zwecke.
BG101284A (bg) Съединения и методи за лечение на рак
ES2119185T3 (es) Tratamiento de enfermedades micobacterianas por administracion de productos de la proteina bactericida/que aumenta la permeabilidad.
ATE215379T1 (de) Antifungaleverfahren und mitteln
FI972308A0 (fi) 2-substituoituja 1,2,5-tiadiatsolidin-3-oni-1,1-dioksideja ja niitä sisältäviä koostumuksia ja menetelmiä niiden käyttämiseksi
DE68910799D1 (de) Faserbehandlungszusammensetzung.
DE68910973D1 (de) Arzneimittelzusammensetzung, enthaltend deoxyribonukleoside für heilung von wunden.
PT88275A (pt) Processo para a preparacao de composicoes farmaceuticas contendo 5-amino ou amino substituido-1,2,3-triazois uteis como agentes antiproliferativos
DE59610251D1 (de) Konjugat, umfassend einen wirkstoff, ein polypeptid und einen polyether
PT804465E (pt) Novos inibidores da elastase
DE69120390D1 (de) Kollagen-bindendes protein sowie dessen herstellung
DE68918479D1 (de) Menschlicher Hitzeschock-Faktor.
PT869785E (pt) 4-hidroxicumarina-3-carboxamidas para o tratamento de diabetes mellitus nao insulinodependente
DE69106533D1 (de) Verdampfer für anästhetische Zwecke.
ATE68486T1 (de) 1-((2-fluorophenyl)(4-fluorophenyl)phenylmethyl - 1h-imidazol.
DE69010897D1 (de) Verwendung von monoklonalen Antikörpern gegen B2-Mikroglobulin.
NO982151D0 (no) Hemoregulatoriske forbindelser
OA09519A (fr) D-acide aspartique b-hydroxamate en tant que medicament
ATE231887T1 (de) Protein mit anti-tumorwirkung
RU95119300A (ru) Средство для лечения длительно незаживающих ран
ES266751U (es) Gafas de sol, sin tratamiento optico, plegable.
ATE117543T1 (de) Ophthalmisches behandlungssystem.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties